Caring for patients with advanced solid tumors?
Consider BrILliance
With limited treatment options for advanced solid tumors, the BrILliance clinical research study is currently underway to investigate potential treatments. Consider BrILliance as an opportunity for your patients with certain solid tumors at an advanced stage to access investigational treatments.
BrILliance is a phase 1/2 clinical study for patients with certain solid tumors at an advanced stage. This study is a first-in-human study evaluating the safety, tolerability, and efficacy of a study drug. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2).
The study drug is administered as an IV infusion once every two weeks, but the dosing schedule may change to once a week or once every three weeks, based on the patient’s response to the study drug. The study drug is an antibody-cytokine fusion protein that works by blocking PD-1, a checkpoint protein on T cells that prevents them from destroying other cells, and by activating IL2, a cytokine that can trigger immune responses. Blocking PD-1 and activating T cells through IL2 simultaneously is expected to help immune cells attack cancer cells.
Patients are expected to participate in this study for as long as they are tolerating the study drug well and deriving benefit. Qualified participants will be reimbursed for travel to and from study visits (fuel and bus/train tickets), as well as food costs.
How can you help?
BrILliance is enrolling approximately 150 people with advanced solid tumors in the US and worldwide. The success of BrILliance depends on physicians to refer potential study participants. Your patients may be eligible if they:
- Are ≥18 years old at screening
- Able to submit archival tissue with optional fresh biopsy (fresh biopsy sample required for Phase 2 dose expansion)
- Have a histologically or cytologically confirmed diagnosis of malignancy (locally advanced or metastatic) with confirmed progression on standard-of-care therapy for dose escalation phase
- Have a ECOG performance status of 0 or 1
Please note: Other protocol-defined inclusion/exclusion criteria apply.
The study team will check your patient’s full medical history to see if they meet all inclusion criteria and none of the exclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented.
If you have potentially eligible and interested patients, empower them with options and discuss BrILliance. You may also contact the nearest study site to refer them.
Find a study site near you!
Your patient’s health and safety are our top priorities. We hope you value the impact of this research and will consider referring potential candidates. With your support, we hope to help patients with advanced solid tumors.
English 
Spanish (United States)